Jhpiego, 1776 Massachusetts Ave,, NW#300, Washington, DC 20036, USA.
BMC Pregnancy Childbirth. 2013 Feb 20;13:44. doi: 10.1186/1471-2393-13-44.
BACKGROUND: Hemorrhage continues to be a leading cause of maternal death in developing countries. The 2012 World Health Organization guidelines for the prevention and management of postpartum hemorrhage (PPH) recommend oral administration of misoprostol by community health workers (CHWs). However, there are several outstanding questions about distribution of misoprostol for PPH prevention at home births. METHODS: We conducted an integrative review of published research studies and evaluation reports from programs that distributed misoprostol at the community level for prevention of PPH at home births. We reviewed methods and cadres involved in education of end-users, drug administration, distribution, and coverage, correct and incorrect usage, and serious adverse events. RESULTS: Eighteen programs were identified; only seven reported all data of interest. Programs utilized a range of strategies and timings for distributing misoprostol. Distribution rates were higher when misoprostol was distributed at a home visit during late pregnancy (54.5-96.9%) or at birth (22.5-83.6%), compared to antenatal care (ANC) distribution at any ANC visit (22.5-49.1%) or late ANC visit (21.0-26.7%). Coverage rates were highest when CHWs and traditional birth attendants distributed misoprostol and lower when health workers/ANC providers distributed the medication. The highest distribution and coverage rates were achieved by programs that allowed self-administration. Seven women took misoprostol prior to delivery out of more than 12,000 women who were followed-up. Facility birth rates increased in the three programs for which this information was available. Fifty-one (51) maternal deaths were reported among 86,732 women taking misoprostol: 24 were attributed to perceived PPH; none were directly attributed to use of misoprostol. Even if all deaths were attributable to PPH, the equivalent ratio (59 maternal deaths/100,000 live births) is substantially lower than the reported maternal mortality ratio in any of these countries. CONCLUSIONS: Community-based programs for prevention of PPH at home birth using misoprostol can achieve high distribution and use of the medication, using diverse program strategies. Coverage was greatest when misoprostol was distributed by community health agents at home visits. Programs appear to be safe, with an extremely low rate of ante- or intrapartum administration of the medication.
背景:在发展中国家,出血仍然是导致产妇死亡的主要原因。2012 年世界卫生组织发布了产后出血(PPH)预防和管理指南,建议由社区卫生工作者(CHWs)为产妇口服米索前列醇。然而,在家中分娩时,米索前列醇用于预防 PPH 的分发仍然存在几个悬而未决的问题。
方法:我们对已发表的研究和在社区一级分发米索前列醇以预防在家中分娩时 PPH 的方案的评估报告进行了综合回顾。我们审查了对最终用户进行教育、药物管理、分发和覆盖范围、正确和错误使用以及严重不良事件的方法和干部。
结果:确定了 18 个方案,只有 7 个报告了所有感兴趣的数据。方案采用了一系列策略和时间分发米索前列醇。与在任何产前检查(ANC)就诊时(22.5-49.1%)或在晚期 ANC 就诊时(21.0-26.7%)分发相比,在孕晚期(54.5-96.9%)或分娩时(22.5-83.6%)为 CHWs 家访分发米索前列醇的分配率更高。当 CHWs 和传统助产士分发米索前列醇时,覆盖率最高,而当卫生工作者/ANC 提供者分发药物时,覆盖率最低。允许自行给药的方案实现了最高的分配和覆盖率。在随访的 12000 多名妇女中,有 7 名妇女在分娩前服用了米索前列醇。在三个提供了这方面信息的方案中,机构分娩率有所增加。在服用米索前列醇的 86732 名妇女中,报告了 51 例产妇死亡:24 例归因于认为的 PPH;没有一例直接归因于米索前列醇的使用。即使所有死亡都归因于 PPH,相当于每 100000 例活产有 59 例产妇死亡(51 例产妇死亡/100000 例活产),也远低于这些国家中的任何一个国家报告的产妇死亡率。
结论:使用米索前列醇预防在家中分娩时 PPH 的基于社区的方案可以通过多种方案策略实现药物的高分配和使用。当米索前列醇由社区卫生代理人在家访时分发时,覆盖率最高。这些方案似乎是安全的,药物在分娩前或分娩时使用的比例极低。
BMC Pregnancy Childbirth. 2013-2-20
BMC Pregnancy Childbirth. 2014-6-4
BMC Pregnancy Childbirth. 2012-10-30
J Midwifery Womens Health. 2016
BMC Pregnancy Childbirth. 2014-2-20
Int J Environ Res Public Health. 2022-3-14
Health Res Policy Syst. 2021-10-12
Lancet Glob Health. 2021-3
BMC Pregnancy Childbirth. 2019-11-6
Einstein (Sao Paulo). 2010-3
BMC Pregnancy Childbirth. 2012-10-30
Int J Gynaecol Obstet. 2012-9-9
Gesundheitswesen. 2012-4
Cochrane Database Syst Rev. 2012-2-15
Semin Perinatol. 2012-2
BMC Pregnancy Childbirth. 2012-1-17
Expert Opin Investig Drugs. 2012-1-11
Int J Gynaecol Obstet. 2011-11-17